The ability of urinary biomarkers to predict residual renal function (RRF) decline in peritoneal dialysis (PD) patients has not been defined. The present study aimed to explore the utility of established biomarkers from kidney injury models for predicting loss of RRF in incident PD patients, and to evaluate the impact on RRF of using neutral-pH PD solution low in glucose degradation products.
Methods
The study included 50 randomly selected participants from the balANZ trial who had completed 24 months of follow-up. A change in glomerular filtration rate (GFR) was used as the primary clinical outcome measure. In a mixed-effects general linear model, baseline measurements of 18 novel urinary biomarkers and albumin were used to predict GFR change. The model was further used to evaluate the impact of biocompatible PD solution on RRF, adjusted for each biomarker.
Results
Baseline albuminuria was not a useful predictor of change in RRF in PD patients (p = 0.84). Only clusterin was a significant predictor of GFR decline in the whole population (p = 0.04, adjusted for baseline GFR and albuminuria). However, the relationship was no longer apparent when albuminuria was removed from the model (p = 0.31). When the effect of the administered PD solutions was examined using a model adjusted for PD solution type, baseline albuminuria, and GFR, higher baseline urinary concentrations of trefoil factor 3 (TFF3, p = 0.02), kidney injury molecule 1 (KIM-1, p = 0.04), and interferon γ–induced protein 10 (IP-10, p = 0.03) were associated with more rapid decline of RRF in patients receiving conventional PD solution compared with biocompatible PD solution.
Conclusions
Higher urinary levels of kidney injury biomarkers (TFF3, KIM-1, IP-10) at baseline predicted significantly slower RRF decline in patients receiving bio-compatible PD solutions. Findings from the present investigation should help to guide future studies to validate the utility of urinary biomarkers as tools to predict RRF decline in PD patients.
BargmanJ.M., ThorpeK.E., ChurchillDN on behalf of the CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.J Am Soc Nephrol2001; 12: 2158–62.
ChoiH.Y., KimD.K., LeeT.H., MoonS.J., HanS.H., LeeJ.E.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.Perit Dial Int2008; 28: 174–82.
6.
FanS.L., PileT., PunzalanS., RafteryM.J., YaqoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2008; 73: 200–6.
7.
PajekJ., KvederR., BrenA., GucekA., BucarM., SkoberneA.Short-term effects of bicarbonate/lactate–buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.Nephrol Dial Transplant2009; 24: 1617–25.
8.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
9.
HaasS., SchmittC.P., ArbeiterK., BonzelK.E., FischbachM., JohnU.Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis.J Am Soc Nephrol2003; 14: 2632–8.
10.
WeissL., StegmayrB., MalmstenG., TejdeM., HadimeriH., SiegertC.E.Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int2009; 29: 647–55.
11.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
12.
ParikovaA., StruijkD.G., ZweersM.M., LangedijkM., SchoutenN., van den BergN.Does the biocompatibility of the peritoneal dialysis solution matter in assessment of peritoneal function?Perit Dial Int2007; 27: 691–6.
13.
BajoM.A., Perez–LozanoM.L., Albar–VizcainoP., del PesoG., CastroM.J., Gonzalez–MateoG.Low-GDP peritoneal dialysis fluid (“Balance”) has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid.Nephrol Dial Transplant2011; 26: 282–91.
14.
Fernandez–PerpenA., Perez–LozanoM.L., BajoM.A., Albar–VizcainoP., CorreaP.S., Del PesoG.Influence of bicarbonate/low-GDP peritoneal dialysis fluid (Bica-Vera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.Perit Dial Int2012; 32: 292–304.
15.
KimS., OhJ., ChungW., AhnC., KimS.G., OhK.H.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant2009; 24: 2899–908.
16.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
17.
KimY.L., DoJ., ParkS.H., ChoK., ParkJ., YoonK.Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report.Nephrology (Carlton)2003; 8(Suppl): S28–32.
18.
KimS.G., KimS., HwangY.H., KimK., OhJ.E., ChungW.Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).Perit Dial Int2008; 28(Suppl 3): S117–22.
19.
Haag–WeberM., KramerR., HaakeR., IslamM.S., PrischlF., HaugU.Low-GDP fluid (Gambrosol Trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
20.
TranæusA.A long-term study of a bicarbonate/lactate– based peritoneal dialysis solution—clinical benefits. The Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20: 516–23.
21.
FerianiM., KirchgessnerJ., La GrecaG., Passlick–DeetjenJ.Randomized long-term evaluation of bicarbonate-buffered CAPD solution.Kidney Int1998; 54: 1731–8.
22.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
23.
JohnsonD.W., ClarkeM., WilsonV., WoodsF., BrownF.G.Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.BMC Nephrol2010; 11: 25.
24.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.Nephrol Dial Transplant2012; 27: 4445–53.
25.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Perit Dial Int2012; 32: 497–506.
26.
HoyW.E., WangZ., VanBuynderP., BakerP.R., McDonaldS.M., MathewsJ.D.The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure.Kidney Int2001; 60: 249–56.
27.
HallanS.I., RitzE., LydersenS., RomundstadS., KvenildK., OrthS.R.Combining GFR and albuminuria to classify CKD improves prediction of ESRD.J Am Soc Nephrol2009; 20: 1069–77.
28.
IsekiK., IkemiyaY., IsekiC., TakishitaS.Proteinuria and the risk of developing end-stage renal disease.Kidney Int2003; 63: 1468–74.
29.
KangS.H., ChoK.H., ParkJ.W., YoonK.W., DoJ.Y.Impact of heavy proteinuria on clinical outcomes in patients on incident peritoneal dialysis.BMC Nephrol2012; 13: 171.
30.
SinghalM.K., BhaskaranS., VidgenE., BargmanJ.M., VasS.I., OreopoulosD.G.Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it.Perit Dial Int2000; 20: 429–38.
31.
DieterleF., PerentesE., CordierA., RothD.R., VerdesP., GrenetO.Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.Nat Biotechnol2010; 28: 463–9.
32.
DvergstenJ., ManivelJ.C., Correa–RotterR., RosenbergM.E.Expression of clusterin in human renal diseases.Kidney Int1994; 45: 828–35.
33.
HidakaS., KranzlinB., GretzN., WitzgallR.Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries.Cell Tissue Res2002; 310: 289–96.
34.
RinnertM., HinzM., BuhtzP., ReiherF., LesselW., HoffmannW.Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine.Cell Tissue Res2010; 339: 639–47.
35.
YuY., JinH., HolderD., OzerJ.S., VillarrealS., ShughrueP.Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury.Nat Biotechnol2010; 28: 470–7.
36.
AstorB.C., KottgenA., HwangS.J., BhavsarN., FoxC.S., CoreshJ.Trefoil factor 3 predicts incident chronic kidney disease: a case–control study nested within the Atherosclerosis Risk in Communities (ARIC) study.Am J Nephrol2011; 34: 291–7.
37.
BonventreJ.V.Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more.Nephrol Dial Transplant2009; 24: 3265–8.
38.
van TimmerenM.M., VaidyaV.S., van ReeR.M., OterdoomL.H., de VriesA.P., GansR.O.High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients.Transplantation2007; 84: 1625–30.
39.
BhavsarN.A., KottgenA., CoreshJ., AstorB.C.Neutrophil gelatinase–associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study.Am J Kidney Dis2012; 60: 233–40.
40.
PanzerU., SteinmetzO.M., ReinkingR.R., MeyerT.N., FehrS., SchneiderA.Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury.J Am Soc Nephrol2006; 17: 454–64.
41.
WolkowP.P., NiewczasM.A., PerkinsB., FicocielloL.H., LipinskiB., WarramJ.H.Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics.J Am Soc Nephrol2008; 19: 789–97.
42.
MatzM., BeyerJ., WunschD., MashreghiM.F., SeilerM., PratschkeJ.Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function.Kidney Int2006; 69: 1683–90.
